Free Newsletter
Court reinstates Pfizer whistleblower suit
A Pfizer whistleblower will get his day in court. Dr. Peter Rost (photo) accused the company of illegally marketing Genotropin, a human growth hormone product; he filed suit after he lost his job (he was a VP at Pharmacia when Pfizer bought the company). Info in Rost's suit led to a $34.7 million fine against Pfizer, but a federal district court threw out his complaint.
Now, the U.S. Court of Appeals has overruled the lower court. The suit will be reinstated, and Rost will have a chance to amend it. The upshot? Rost may get a share of that $34.7 million fine, and Pfizer may be vulnerable to additional fines. The drugmaker said in a statement that it's confident it will prevail--and emphasized that it was Pharmacia that promoted Genotropin for youth, beauty, and athletic prowess.
- check out Pfizer's statement at Rost's blog
- read this Pharmalot item
Related Articles:
Pfizer leaves exec dangling. Report
Grassley: Whistleblowers, call me. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: